Skip to main content
Signal8

NBY (NBY)

NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc.

NASDAQ:NBYHealthcare
Mkt Cap-
Float15.26M
O/S-
Inst Own-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
SectorHealthcare
IndustryBiotechnology
ExchangeNYSE American
CountryUSUS
IPO DateOct 26, 2007
Shares Outstanding-
Float15.26M
Company Overview

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology.

Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris.

The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments.

The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007.

Its corporate headquarters are located in Emeryville, California.

Leadership

David E. Lazar

Chief Executive Officer of NovaBay

Justin M. Hall, Esq.

Director

Mijia (Bob) Wu, M.B.A.

Director

Mr. Hall

Vice President of Business Development, General Counsel and Corporate Secretary

Employees

13

Country

US

Sector

Healthcare

Website

novabay.com

Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
No price targets available
Ratings Distribution
BUY
2
HOLD
3
SELL
0
TOTAL5
Insider Trades
InsiderTypeShares
R01 Fund LP profile photoR01 Fund LPConversion of Derivative56.81M
Framework Ventures IV L.P. profile photoFramework Ventures IV L.P.Conversion of Derivative56.81M
Lazar David E. profile photoLazar David E.Option Exercise39.9K
Lazar David E. profile photoLazar David E.Grant/Award6.39M
Kazley Michael John profile photoKazley Michael JohnConversion of Derivative56.81M
Lazar David E. profile photoLazar David E.Sale441.3K
Shareholders
--
Institutional
(22)
--
Insiderⓘ
(1)
--
5%+ Owners
(5)
--
Unattributed (incl. retail)ⓘ
Top Shareholders
NameShares%
Kazley Michael John logo
Kazley Michael John
· joint filing· may incl. warrants· filed Jul 2026
53.6M52.4%
Framework Ventures IV L.P. logo
Framework Ventures IV L.P.
· joint filing· may incl. warrants· filed Jul 2026
47.7M46.6%
R01 Fund LP profile photo
R01 Fund LP
10% Owner
22.7M--
Sky Frontier Foundation logo
Sky Frontier Foundation
· filed Sep 2026
0+5.6M via warrants9.9%
David E. Lazar logo
David E. Lazar
· may incl. warrants· filed Jan 2026
1.3M5.0%
BlackRock, Inc. logo
BlackRock, Inc.
424.7K--
VANGUARD CAPITAL MANAGEMENT LLC logo
VANGUARD CAPITAL MANAGEMENT LLC
327.0K--
GEODE CAPITAL MANAGEMENT, LLC logo
GEODE CAPITAL MANAGEMENT, LLC
281.5K--
Poplar Point Capital Management LLC logo
Poplar Point Capital Management LLC
· may incl. warrants· filed Mar 2026
204.1K0.8%
POPLAR POINT CAPITAL PARTNERS LP profile photo
POPLAR POINT CAPITAL PARTNERS LP
10% Owner
204.1K--
Sources: 13F, Form 4, 13D/13G
Insiders & Institutional Holders
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
TTM Yield
--
Annual (LTM)
--
Latest
$0.8000
Sep 30, 25
5Y Growth
--
Compliance Status
Loading compliance data...